FGF23 and chronic kidney disease: Recent studies have also suggested that in patients with non-dialysis CKD, lower soluble Klotho levels in combination with higher FGF-23 levels are associated with adverse clinical outcomes, including overall mortality and cardiovascular events in non-diabetic non-dialysis CKD patients [55,65].